Grant: Catalyst Grant:Infection & Immunity-PHAC-CAID/Hep C Res Init/Biomed/clin stream
Université Laval
$99,902.00
Development of a candidate vaccine to hepatitis C virus using an innovative virus like particles (VLPs) technology
FY 2009-10
Summary
The world health organisation (WHO) estimates that hepatitis C virus (HCV) infection affects about 200 million people, which correspond to 3% of the world population. It is considered as one of the most devastating infectious disease worldwide.
Because HCV is a virus that mutates rapidly, like HIV and influenza virus, it appears that vaccines that are based only on the induction of an antibody response to the surface glycoproteins will not be very efficient. Therefore, the development of a CTL response to highly conserved epitopes of HCV is considered as the most promising solution in the development of a vaccine toward this disease. We have developed a vaccine platform based on the use of virus like particles (VLPs) that is able to trigger efficiently a CTL response in mouse and in human cells. We propose to use this platform with the conserved HCV antigens core. We will validate the efficacy of our constructs in a mouse model using a vaccinia virus expressing the core protein. We hope to direct the immune response at the weakest points of the virus that are the highly conserved CTL epitopes located in core which should make this vaccine potentially able to induce protection to all strains of the virus.
Department
Program
Catalyst Grant:Infection & Immunity-PHAC-CAID/Hep C Res Init/Biomed/clin stream
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
198509
Name
Leclerc Denis
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant: Infection and Immunity
Projecttitle
Development of a candidate vaccine to hepatitis C virus using an innovative virus like particles (VLPs) technology
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$99,902
Cihrequipment2
$0
Programname2
Catalyst Grant:Infection & Immunity-PHAC-CAID/Hep C Res Init/Biomed/clin stream
Keyworddelim
Adjuvant; Core Protein; Hepatitis C Virus; Papaya Mosaic Virus; Vaccine Development; Virus Like Particles
Abstract
The world health organisation (WHO) estimates that hepatitis C virus (HCV) infection affects about 200 million people, which correspond to 3% of the world population. It is considered as one of the most devastating infectious disease worldwide.
Because HCV is a virus that mutates rapidly, like HIV and influenza virus, it appears that vaccines that are based only on the induction of an antibody response to the surface glycoproteins will not be very efficient. Therefore, the development of a CTL response to highly conserved epitopes of HCV is considered as the most promising solution in the development of a vaccine toward this disease. We have developed a vaccine platform based on the use of virus like particles (VLPs) that is able to trigger efficiently a CTL response in mouse and in human cells. We propose to use this platform with the conserved HCV antigens core. We will validate the efficacy of our constructs in a mouse model using a vaccinia virus expressing the core protein. We hope to direct the immune response at the weakest points of the virus that are the highly conserved CTL epitopes located in core which should make this vaccine potentially able to induce protection to all strains of the virus.
Competitiondate
200909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leclerc, Denis
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,902~ $0~